Effects of OCT2 and MDR1 gene polymorphisms on vancomycin concentration and clinical efficacy in infants

doi:10.12092/j.issn.1009-2501.2018.02.007

Abstract

Abstract:

AIM: To study the effects of organic cation transporter 2 (OCT2) and multidrug resistance gene 1 (MDR1) gene polymorphisms on plasma concentration and clinical efficacy of vancomycin in infants. METHODS: Ninety-one infants that treated with vancomycin were recruited. The plasma concentrations of vancomycin were measured by enzyme multiplied immunoassay technique. The genotypes of OCT2 G808T (rs316019) and MDR1 C3435T (rs1045642) were determined by polymerase chain reaction followed with direct sequencing. The association between different genotypes and the concentrations and clinical efficacy of vancomycin were analyzed. RESULTS: There were 16.5% patients which the concentration reached 10-20 μg/mL. The curative effect of 5-<10 μg/mL (88%) and 10-20 μg/mL (93.3%) were significant higher than that of <5 μg/mL (44%) (P<0.05); and the curative effect of 5-<10 μg/mL and 10-20 μg/mL were similar. The plasma concentration (10.15±2.35) μg/mL and concentration/dose values (0.98±0.27) μg·mL^-1·mg^-1·kg of vancomycin in infants with OCT2 TT genotype were significantly increased than that of OCT2 GG genotypes (6.92±2.83) μg/mL, (0.59±0.22) μg·mL^-1·mg^-1·kg (P<0.05). Meanwhile, the clinical efficacy of vancomycin in TT genotype (100%) was higher than that in GG genotype (73.2%) (P<0.05). However, the concentration and clinical efficacy of vancomycin in the infants with mutant type and wild type of MDR1 C3435T were similar (P>0.05). CONCLUSION: OCT2 G808T polymorphism is associated with the plasma concentrations and clinical efficacy of vancomycin in infants.

Key words: vancomycin, drug transporter, polymorphisms, plasma concentration, infant

CLC Number:

R971.6

CHEN Yaoyao，SHI Daohua，LIU Guanghua，NIU Peiguang，LIU Baichen. Effects of OCT2 and MDR1 gene polymorphisms on vancomycin concentration and clinical efficacy in infants[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(2): 154-158.

References

［1］Abdel Hadi O, Al Omar S, Nazer LH, et al. Vancomycin pharmacokinetics and predicted dosage requirements in pediatric cancer patients［J］. J Oncol Pharm Pract, 2016, 22(3): 448-453.
［2］ Hou W, Zhang D, Lu W, et al. Polymorphism of organic cation transporter 2 improves glucose-lowering effect of metformin via influencing its pharmacokinetics in Chinese type 2 diabetic patients［J］. Mol Diagn Ther, 2015, 19(1): 25-33.
［3］Wolking S, Schaeffeler E, Lerche H, et al. Impact of genetic polymorphisms of ABCB1 (MDR1, P-Glycoprotein) on drug disposition and potential clinical implications: update of the literature［J］. Clin Pharmacokinet, 2015, 54(7): 709-735.
［4］周源，卢雪玲，赵军，等. 新疆维吾尔族人群SLC22A2中rs316019位点基因多态性分布研究［J］. 中国临床药理学与治疗学，2017, 22(3): 287-293.
［5］Christensen MM, Pedersen RS, Stage TB, et al. A gene-gene interaction between polymorphisms in the OCT2 and MATE1 genes influences the renal clearance of metformin［J］. Pharmacogenet Genomics, 2013, 23(10): 526-534.
［6］Amin ML. P-glycoprotein inhibition for optimal drug delivery［J］. Drug Target Insights, 2013, 7: 27-34.
［7］Sun H, Frassetto L, Benet LZ. Effects of renal failure on drug transport and metabolism［J］. Pharmacol Ther, 2006, 109(1-2): 1-11.
［8］付孟龙，周宏灏. MDR1基因多态性及其临床相关性［J］. 中国临床药理学与治疗学，2016, 21(4): 463-469.
［9］抗菌药物临床试验技术指导原则写作组. 抗菌药物临床试验技术指导原则［J］. 中国临床药理学杂志，2014, 30(9): 844-856.
［10］张鞠玲，耿伟，崔恩博，等. 肝硬化合并自发性细菌性腹膜炎病原学特征分析［J］. 临床肝胆病杂志，2015, 31(3): 407-412.
［11］Ye ZK, Chen YL, Chen K, et al. Therapeutic drug monitoring of vancomycin: a guideline of the division of therapeutic drug monitoring, chinese pharmacological society［J］. J Antimicrob Chemother, 2016, 71(11): 3020-3025.
［12］Chen J, Brockmoller J, Seitz T, et al. Tropane alkaloids as substrates and inhibitors of human organic cation transporters of the SLC22 (OCT) and the SLC47 (MATE) families［J］. Biol Chem, 2017, 398(2): 237-249.
［13］Yoon H, Cho HY, Yoo HD, et al. Influences of organic cation transporter polymorphisms on the population pharmacokinetics of metformin in healthy subjects［J］. AAPS J, 2013, 15(2): 571-580.

[1]	WU Lili, LIANG Zhi, HUANG Siyong, WANG Yan. Effect of augmented renal clearance (ARC) on the pharmacokinetics, efficacy, and safety of vancomycin in patients with infective endocarditis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(10): 1139-1145.
[2]	CHEN Jiayin, WANG Li, WANG Lijun, TONG Gangling, MA Jie, CHEN Xijing, LU Yang. Correlation between organic cation transporter gene polymorphisms and the toxicities and clinical response of oxaliplatin [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(2): 171-177.
[3]	HU Yin, YANG Dandan, XU Yichao, SHAO Rong, RUAN Zourong, JIANG Bo, CHEN Jinliang, LOU Honggang. Application of artificial neural network model in bioequivalence study of candesartan cilexetil tablets [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(1): 63-69.
[4]	LIN Liangmo, FU Xiangjun, ZHONG Lili, WANG Hefang, WU Qiongshi, XIAO Jian. Establishment of population pharmacokinetics model of vancomycin in patients with Neutropenia [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(9): 1014-1022.
[5]	ZHANG Yuanjin, HUANG Shengbo, LIU Jie, WANG Xin. Construction and application of innovation gene-edited rats and intestinal 3D organoids models in drug metabolism and pharmacokinetics [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(8): 914-922.
[6]	FU Xiangjun, HUANG Li, GUO Li, LIN Liangmo. Application of AUC/MIC as the therapeutic drug monitoring target of vancomycin in patients with severe infections of multi drug resistant gram positive bacteria [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(7): 775-781.
[7]	WU Wei, CHEN Zheng, DU Zhen, QU Shuangquan. Vinpocetine improves the long-term cognitive function of infant rats induced by sevoflurane via Wnt/GSK3β/β-catenin signaling pathway [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(5): 539-545.
[8]	GUO Xianzhong, LIN Rongfang, LIN Weiwei. Development of software for individualizing dosage regimens of vancomycin based on population pharmacokinetics models [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(1): 30-39.
[9]	YANG Qinyan, HUANG Li, SHI Lan, OU Yuanyuan, LI Guoyuan, HUANG Chengyong. Median effective plasma concentration of propofol inhibiting body movement when combined with butorphanol in patients undergoing hysteroscopic surgery [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(9): 1033-1037.
[10]	GUO Mingxing, GUO Heng, SHEN Su, SUN Liying, CUI Xiangli. Retrospective analysis of voriconazole in the monitoring of therapeutic drugs in patients with liver dysfunction [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(7): 757-763.
[11]	CHEN Chao, ZHENG Qingshan, LI Lujin, LI Xue, XU Ling. Comparison of the calculation approaches of AUC in non-compartment model pharmacokinetics [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(12): 1381-1387.
[12]	CHEN Yan, ZHU Lijun, FANG Zhengmei, ZHU Hui, JIN Yuelong, SHEN Chong, YAO Yingshui. Association of insulin-like growth factor(IGF)-1 polymorphisms and efficacy of antihypertensive drugs [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(2): 171-179.
[13]	ZHU Min, ZHANG Cuifeng, GUO Yiyun, ZHU Ziming. Population pharmacokinetics of vancomycin in elderly infectious patients [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(2): 158-163.
[14]	LI Li, LI He, LIU Xing'e, WEI Nan. Determination of apatinib in tumor patients' plasma by liquid chromatography tandem mass spectrometry and its application [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(7): 790-795.
[15]	WEI Liuping, WU Qing, YIN Nange, YANG Bin, MAO Jinxiao. Effect and safety of lactoferrin for prevention of late-onset sepsis in premature neonates: a systematic review [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(6): 653-660.